Genotype-specific development of MEN 2 constituent components in 683 RET carriers.

Endocrine-related cancer Pub Date : 2024-06-10 Print Date: 2024-07-01 DOI:10.1530/ERC-24-0038
Andreas Machens, Kerstin Lorenz, Frank Weber, Tim Brandenburg, Dagmar Führer-Sakel, Henning Dralle
{"title":"Genotype-specific development of MEN 2 constituent components in 683 RET carriers.","authors":"Andreas Machens, Kerstin Lorenz, Frank Weber, Tim Brandenburg, Dagmar Führer-Sakel, Henning Dralle","doi":"10.1530/ERC-24-0038","DOIUrl":null,"url":null,"abstract":"<p><p>The age-specific development of the three constituent components of multiple endocrine neoplasia type 2 (MEN 2) is incompletely characterized for many of the >30 causative rearranged during transfection (RET) mutations, which this genetic association study aimed to specify. Included in the study were 683 carriers of heterogeneous RET germline mutations: 53 carriers with 1 highest-risk mutation (codon 918); 240 carriers with 8 different high-risk mutations (codon 634); 176 carriers with 16 different intermediate-risk mutations (codon 609, 611, 618, 620, or 630); and 214 carriers with 6 different low-risk mutations (codon 768, 790, 804, or 891).There was a strong genotype-specific development of MEN 2 constituent components, with distinct age gradients from C cell disease to node negative medullary thyroid cancer (MTC), from node negative to node positive MTC, from node positive MTC to pheochromocytoma, and from pheochromocytoma to primary hyperparathyroidism. Primary hyperparathyroidism was not observed among the 53 MEN 2B patients who carried highest-risk mutations (age range: 0.5-50 years), of whom no more than 12 (23%) and 3 (6%) carriers were older than age 30 years and 35 years, respectively. The age-specific development of MTC differed significantly between the four RET risk categories, whereas the age-specific development of pheochromocytoma differed significantly only between the two strongest RET risk categories. No significant differences were noted in the development of primary hyperparathyroidism. These findings delineate age-specific disease manifestation corridors for the three constituent components of MEN 2 by RET genotype. These corridors are useful for initial risk assessment and organ-specific surveillance of newly identified RET carriers going forward.</p>","PeriodicalId":93989,"journal":{"name":"Endocrine-related cancer","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine-related cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1530/ERC-24-0038","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/1 0:00:00","PubModel":"Print","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The age-specific development of the three constituent components of multiple endocrine neoplasia type 2 (MEN 2) is incompletely characterized for many of the >30 causative rearranged during transfection (RET) mutations, which this genetic association study aimed to specify. Included in the study were 683 carriers of heterogeneous RET germline mutations: 53 carriers with 1 highest-risk mutation (codon 918); 240 carriers with 8 different high-risk mutations (codon 634); 176 carriers with 16 different intermediate-risk mutations (codon 609, 611, 618, 620, or 630); and 214 carriers with 6 different low-risk mutations (codon 768, 790, 804, or 891).There was a strong genotype-specific development of MEN 2 constituent components, with distinct age gradients from C cell disease to node negative medullary thyroid cancer (MTC), from node negative to node positive MTC, from node positive MTC to pheochromocytoma, and from pheochromocytoma to primary hyperparathyroidism. Primary hyperparathyroidism was not observed among the 53 MEN 2B patients who carried highest-risk mutations (age range: 0.5-50 years), of whom no more than 12 (23%) and 3 (6%) carriers were older than age 30 years and 35 years, respectively. The age-specific development of MTC differed significantly between the four RET risk categories, whereas the age-specific development of pheochromocytoma differed significantly only between the two strongest RET risk categories. No significant differences were noted in the development of primary hyperparathyroidism. These findings delineate age-specific disease manifestation corridors for the three constituent components of MEN 2 by RET genotype. These corridors are useful for initial risk assessment and organ-specific surveillance of newly identified RET carriers going forward.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
683 名 RET 携带者中 MEN 2 组成成分的基因型特异性发展。
在多发性内分泌肿瘤 2 型(MEN 2)的 3 个组成成分中,有超过 30 个致病基因在转染过程中发生了重排(RET)突变,而这些基因的年龄特异性发展特征尚不完全,本遗传关联研究旨在明确这一点。这项研究包括 683 名异质性 RET 基因突变携带者:53 名携带者有 1 个最高风险突变(密码子 918);240 名携带者有 8 个不同的高风险突变(密码子 634);176 名携带者有 16 个不同的中风险突变(密码子 609、611、618、620 或 630);214 名携带者有 6 个不同的低风险突变(密码子 768、790、804 或 891)。MEN 2 的组成成分有很强的基因型特异性,从 C 细胞病到结节阴性 MTC、从结节阴性到结节阳性 MTC、从结节阳性 MTC 到嗜铬细胞瘤、从嗜铬细胞瘤到原发性甲状旁腺功能亢进的年龄梯度明显。在 53 例携带最高风险突变(年龄范围为 0.5-50 岁)的 MEN 2B 患者中,未观察到原发性甲状旁腺功能亢进,其中年龄超过 30 岁和 35 岁的携带者分别不超过 12 人(23%)和 3 人(6%)。在 4 个 RET 风险类别中,MTC 的年龄特异性发展有显著差异,而嗜铬细胞瘤的年龄特异性发展仅在 2 个最强 RET 风险类别中存在显著差异。原发性甲状旁腺机能亢进症的发病情况则没有明显差异。这些研究结果根据 RET 基因型为 MEN 2 的 3 个组成成分划定了特定年龄的疾病表现走廊。这些走廊有助于对新发现的RET基因携带者进行初步风险评估和器官特异性监测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Chromosomal alteration patterns in PitNETs: massive losses in aggressive tumors. The complex landscape of luminal breast cancer. Living with a RET gene mutation: patient perspectives. Friend or foe? Deciphering androgen receptor action to improve bipolar androgen therapy for prostate cancer. Mechanisms of RET-mediated signal transduction.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1